EGFR and non-small cell lung carcinoma: Osimertinib is recommended for the treatment of patients with metastatic NSCLC who progressed on or after EGFR TKI therapy and who exhibit a specific T790M mutation, as detected by a U.S. Food and Drug Administration (FDA)-approved test (NCCN, 2016; AstraZeneca, 2015b).